Grifols (NASDAQ:GRFS – Get Free Report) and Altimmune (NASDAQ:ALT – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, earnings and profitability.
Volatility and Risk
Grifols has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500.
Profitability
This table compares Grifols and Altimmune’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Grifols | 5.54% | 6.21% | 2.39% |
| Altimmune | N/A | -31.41% | -26.96% |
Insider & Institutional Ownership
78.0% of Altimmune shares are held by institutional investors. 0.2% of Grifols shares are held by company insiders. Comparatively, 1.6% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings for Grifols and Altimmune, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Grifols | 1 | 2 | 0 | 0 | 1.67 |
| Altimmune | 1 | 1 | 8 | 0 | 2.70 |
Grifols presently has a consensus price target of $10.00, indicating a potential upside of 32.28%. Altimmune has a consensus price target of $14.33, indicating a potential upside of 576.10%. Given Altimmune’s stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Grifols.
Earnings and Valuation
This table compares Grifols and Altimmune”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Grifols | $7.42 billion | 0.69 | $454.82 million | $0.19 | 39.79 |
| Altimmune | $40,000.00 | 10,309.56 | -$88.09 million | ($0.78) | -2.72 |
Grifols has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.
Summary
Grifols beats Altimmune on 8 of the 14 factors compared between the two stocks.
About Grifols
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
About Altimmune
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.
